HARVARD BIOSCIENCE INC — Director's Dealing 2019

Jul 9, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: HARVARD BIOSCIENCE INC (HBIO)
CIK: 0001123494
Period of Report: 2019-07-08

Reporting Person: Green James W (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-07-08	Common Stock	D	5275	$0.00	Disposed	210737	Direct
2019-07-08	Common Stock	A	202875	$0.00	Acquired	413612	Direct
2019-07-08	Common Stock	A	243072	$0.00	Acquired	656684	Direct
2019-07-08	Common Stock	A	418360	$0.00	Acquired	1075044	Direct
2019-07-08	Common Stock	A	418360	$0.00	Acquired	1493404	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	2000	Indirect

Footnotes

F1: The subject restricted stock units were granted to the Reporting Person on January 2, 2019 and were forfeited as a result of the Reporting Person transitioning to his role as President and Chief Executive of the Issuer as of July 8, 2019, and stepping down from his roles as member of the Governance Committee and member of the Compensation Committee.

F2: Includes (a) deferred stock award of 35,100 restricted stock units which fully vest on the earlier of (i) the date of the Issuer's next Annual Meeting of Stockholders after May 16, 2019, immediately prior to the commencement of such meeting, and (ii) May 23, 2020; and (b) 175,637 shares of common stock held by the Reporting Person.

F3: Represents a deferred stock award of 202,875 restricted stock units which shall fully vest on July 8, 2020.

F4: Includes the equity described in footnotes (2) and (3).

F5: Represents a deferred stock award of 243,072 restricted stock units which shall fully vest on July 8, 2021.

F6: Includes the equity described in footnotes (2), (3) and (5).

F7: Represents a deferred stock award of 418,360 restricted stock units which shall vest in four equal installments on January 1, 2020, 2021, 2022 and 2023.

F8: Includes the equity described in footnotes (2), (3), (5) and (7).

F9: Represents a deferred stock award of 418,360 restricted stock units with performance based vesting conditions. These restricted stock units shall vest based on the achievement of a relative total shareholder return of the Issuer's common stock from July 8, 2019 to the earlier of (i) July 8, 2020 or (ii) upon a change of control (measured relative to the NASDAQ Biotechnology index). The target number of these restricted stock units that may be earned is reported above; the maximum amount is 150% of the number reported.

F10: Includes the equity described in footnotes (2), (3), (5), (7) and (9).